Drug Info: ApoThera Drug Disease Clinical Support App
Rinvoq (upadacitinib) receives FDA approval for the treatment of adults with moderately to severely active Ulcerative Colitis (UC)
Induction Dose
– 45 mg by mouth daily x 8 weeks
Maintenance Dose
– 15 mg by mouth daily
– Use lowest effective dosage needed to maintain response
– Discontinue if unable to achieve adequate therapeutic response with 30 mg/day
Refractory, Severe or Extensive UC
– 30 mg by mouth daily
– Discontinue if unable to achieve adequate therapeutic response with 30 mg/day
